Insmed’s Price Target Soars to $67: A Closer Look at the Analyst Upgrade
Key Takeaways: π° Insmed’s price target raised to $67 by TD Cowen analysts π Analysts maintain Buy rating for Insmed π Best case scenario ASPEN data drives high probability of approvals in US, EU, and JP π©ββοΈ Clinically meaningful effect size with strong statistical significance π Model predicts $3.4B in peak sales with $30K gross … Read more